Activin, a member of the TGF␤ superfamily, is a negative regulator of cell growth and prolactin (PRL) production in pituitary lactotrope cells. However, the mechanisms by which this growth factor exerts its growth-inhibitory and -repressive effect on PRL remain unclear. In this study, we show that activin negatively regulates PRL expression at the transcriptional level through the Smad pathway and the multiple endocrine neoplasia type 1 gene product, menin. Our results also demonstrate that the tumor suppressor menin is required for activininduced growth arrest of somatolactotrope cells. Moreover, we show that activin represses transcription and expression of Pit-1, a pituitary transcription factor that is essential for maintenance and development of lactotrope cells. We defined Pituitary gland function is controlled by a large array of hormones and growth factors. Activin, a member of the TGF␤ family, regulates the secretion of a variety of endocrine products (1) and plays an important role in regulating anterior pituitary gland function. Activin was first isolated from the gonads because of its ability to stimulate pituitary FSH synthesis and secretion from the gonadotropes (2). The pituitary action of activin is not restricted to gonadotropes, and activin also modulates the function of other pituitary cell types such as the somatotropes and lactotropes. In addition to stimulating FSH release from the gonadotropes, activin inhibits basal GH and ACTH secretion (2). Finally, activin acts as a negative regulator of PRL expression and secretion in pituitary primary culture and cell lines (3). In addition, activin regulates cell growth and differentiation of numerous cell types. The antiproliferative and proapoptotic effects of activin have been observed in many different cell types such as erythroleukemia (4), capillary endothelial (5), immune (6, 7), breast cancer (8-10), and hepatocytes (11-15). Consistent with the critical role of activin in cell growth regulation, alterations of the activin signaling pathway, such as mutation or truncation of the activin receptor, are associated with human tumors (16, 17) .
Pituitary gland function is controlled by a large array of hormones and growth factors. Activin, a member of the TGF␤ family, regulates the secretion of a variety of endocrine products (1) and plays an important role in regulating anterior pituitary gland function. Activin was first isolated from the gonads because of its ability to stimulate pituitary FSH synthesis and secretion from the gonadotropes (2) . The pituitary action of activin is not restricted to gonadotropes, and activin also modulates the function of other pituitary cell types such as the somatotropes and lactotropes. In addition to stimulating FSH release from the gonadotropes, activin inhibits basal GH and ACTH secretion (2) . Finally, activin acts as a negative regulator of PRL expression and secretion in pituitary primary culture and cell lines (3) . In addition, activin regulates cell growth and differentiation of numerous cell types. The antiproliferative and proapoptotic effects of activin have been observed in many different cell types such as erythroleukemia (4), capillary endothelial (5), immune (6, 7) , breast cancer (8) (9) (10) , and hepatocytes (11) (12) (13) (14) (15) . Consistent with the critical role of activin in cell growth regulation, alterations of the activin signaling pathway, such as mutation or truncation of the activin receptor, are associated with human tumors (16, 17) .
Activin signals through a complex of two transmembrane serine/threonine kinase receptors (type I and type II receptors) (4, 18) . Upon ligand binding, the type II receptor phosphorylates the type I receptor, and the activated receptor complex then recruits and phosphorylates the receptor-regulated Smad2 and Smad3 (18) (19) (20) (21) . These C-terminally phosphorylated Smads then undergo a change in conformation, which results in dissociation from the receptor complex and association with the common-partner Smad4 (22) (23) (24) . The Smad complex translocates into the nucleus where it regulates transcription of target genes through DNA binding and functional recruitment of specific transcription factors and coregulators, thus providing tissue specificity (25, 26) . However, the mechanisms and signaling pathways by which activin regulates lactotrope pituitary cell function and growth are not well characterized.
An important player in regulating both PRL and GH expression is the pituitary-specific transcription factor Pit-1 (GH factor-1) (27, 28) . Pit-1 is required for the generation and maintenance of three cell types (lactotropes, somatotropes, and thyrotropes) in the anterior pituitary gland (29) . Although activin was reported to apparently not modulate Pit-1 mRNA levels (30) , it was shown to induce Pit-1 degradation in MtTW15 somatotrope cells (31) . However, the mechanisms by which activin controls Pit-1 activity are still not fully determined.
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized by endocrine tumors of parathyroids, pancreatic islets, and anterior pituitary, especially prolactinomas (32) . Interestingly, overexpression of menin, the product of the MEN1 gene, leads to reduced PRL expression (33) . Moreover, inactivation of menin expression suppresses TGF␤-induced growth inhibition (34) . We recently showed that menin physically interacts with Smad3 in somatolactotrope cells, and its inactivation blocks TGF␤ signaling (34) . However, such a role for menin downstream of the activin receptor signaling pathway remains to be determined.
The multiple effects of activin on hormone production and secretion highlight the important role played by this growth factor in regulating pituitary function. However, the mechanisms remain unclear. In this study, we show that activin negatively regulates PRL gene transcription and that the Smad pathway is involved in the mediation of this effect. Moreover, we show, for the first time, that menin is required for activin-mediated inhibition of PRL expression. We also show that activin-mediated inhibition of PRL expression occurs through reduction of Pit-1 expression, and we define two Pit-1 sites in the proximal region of the PRL gene promoter as critical to activin-mediated PRL inhibition. Finally, we found that menin is also important for activin-induced cell growth inhibition in somatolactotrope cells. Together, our results clearly demonstrate a critical role for the growth factor activin in regulating inhibition of pituitary cell growth and Pit-1/ PRL expression through the Smads and menin.
RESULTS

Activin Inhibits PRL Gene Transcription
To first characterize the role of activin on PRL gene expression, we used rat somatolactotrope GH4C1 cells, a highly differentiated neuroendocrine cell line that retains the capacity to synthesize and secrete GH and PRL in a hormone-regulated manner (35, 36) . The GH4 cells were established from rat pituitary tumor cells and are widely used as an in vitro model of pituitary tumors (37, 38) . As shown in Fig. 1A (upper panel), PRL mRNA levels were markedly reduced after 4 h of activin treatment and had returned to basal A, Total RNA from GH4C1 cells stimulated with activin for the indicated periods of time were analyzed by Northern blot using specific probes for PRL and GAPDH. B, Whole-cell lysates from GH4C1 cells stimulated with activin for the indicated periods of time were analyzed by Western blot using anti-PRL antibody. The membrane was reprobed with an anti-Stat3 antibody for loading control. C and D, GH4C1 cells were transfected with the rPRL-3kb or the hPRL-5kb (panel C) or the indicated truncated promoter constructs (panel D) with a ␤-galactosidase expression plasmid, and the activin response was measured by luciferase assay 18 h after stimulation. *, P Ͻ 0.05 compared with no activin treatment (all panels). levels by 24 h. Reprobing of the stripped membrane for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA showed equal loading (Fig. 1A, lower panel) . To then evaluate whether the effect of activin on PRL mRNA was followed by a decrease in PRL protein expression, extracts of GH4C1 cells treated or not with activin for different periods of time were analyzed by Western blot. As shown in Fig. 1B (upper panel) , activin clearly inhibited PRL expression by 16 h to reach a maximum inhibition by 24 h. Reprobing of the membrane for signal transducer and activator of transcription (Stat)3 protein showed equal loading (Fig. 1B,  lower panel) . The data indicate that activin blocks PRL gene expression. The same results were obtained using another pituitary-derived PRL-expressing tumor cell line (GH3), thus strengthening the conclusion (data not shown).
To determine whether activin directly regulates PRL expression at the transcriptional level, GH4C1 cells were transfected with reporter constructs containing either 3 kb of the rat PRL promoter fused with the luciferase gene (rPRL-3kb) (39) or 5 kb of the human PRL promoter (hPRL-5kb) (40) and stimulated or not with activin for 16 h. As shown in Fig. 1C , activin stimulation led to a 50% reduction in luciferase activity compared with control. Thus, activin exerts a direct transcriptional effect on PRL gene expression.
The PRL gene promoter consists of distal and proximal regions that both contain important regulatory sequences. To explore further the promoter sequences mediating activin down-regulation of PRL expression, constructs containing both distal and proximal regions of the rat (rPRL-3kb) and human (hPRL-5kb) PRL gene promoters and constructs containing only the proximal elements (rPRL-450bp and hPRL-250bp) fused to the luciferase reporter gene were used. The constructs were transfected into GH4C1 cells, and the luciferase activity was measured after activin treatment. As shown in Fig. 1D , removal of the distal element of both rat and human promoters did not affect PRL-induced repression (rPRL-450bp, hPRL-250bp). The results indicate that activin mediates its inhibitory effect on PRL gene transcription through the proximal region of the PRL gene promoter.
Smad Pathway Is Critical for Inhibition of PRL Gene Transcription by Activin
The Smad pathway represents the canonical pathway downstream of activin receptors. Activin signaling via activation of Smads was demonstrated by immunoblot analysis using a specific antibody to phosphoSmad2. Activin treatment of GH4C1 cells led to a rapid increase in endogenous Smad2 phosphorylation ( Fig.  2A, upper panel) . The membrane was stripped and reprobed with an anti-Stat3 antibody to show equal loading ( Fig. 2A, lower panel) .
To investigate the role of the Smads in the activin-induced PRL inhibition, we used the inhibitory Smad7 (41), the dominant-negative forms of Smad2 (DNSmad2) (23) , and Smad3 (DNSmad3) (42) in which the serine residues within the motif SSXS, the target of Smad phosphorylation by the type I receptor, are mutated to alanine. GH4C1 cells were transiently cotransfected with the 3-kb PRL gene promoter reporter construct and the cDNA encoding for either Smad7, DNSmad2, or DNSmad3. As shown in Fig. 2B , the activin-induced decrease in luciferase activity observed in control cells is blocked in GH4C1 cells overexpressing Smad7 or the dominant negative Smad2 or 3. These results clearly demonstrate the requirement of the Smad pathway in activin-mediated inhibition of PRL gene promoter activation.
Menin Is Required for Activin-Mediated Inhibition of PRL Expression
Interestingly, a recent study showed that overexpression of menin in GH3 pituitary cells inhibits PRL gene expression (33) . To explore the function of menin in activin signaling, GH4C1 cells were treated with either antisense oligonucleotides to the 5Ј-coding sequence of menin (AS-oligo) or a scrambled sequence as a control (C-oligo). To validate our system, we examined the ability of the antisense oligonucleotide to suppress menin expression. As shown in Fig. 3A , treatment of GH4C1 cells with the AS-oligo significantly inhibited A, GH4C1 cells were treated with activin (0-60 min.) Whole-cell lysates were analyzed by Western blot using a specific antibody to phospho-Smad2 (upper panel). The membrane was stripped and reprobed with an anti-Stat3 antibody as a loading control. B, GH4C1 cells were transfected with the PRL-3kb reporter construct, the ␤-galactosidase expression plasmid, and the different Smad expression plasmids, as indicated. Cells were then stimulated with activin and assessed for luciferase activity. *, P Ͻ 0.05 compared with no activin treatment. menin protein expression by 75% as compared with the C-oligo. Densitometric analysis was performed using Fluorochem 8000 software that allows normalization and quantitative analysis of chemiluminescence under nonsaturating condition. To then examine the effects of menin inactivation on activin-mediated PRL inhibition, GH4C1 cells were treated with AS-oligo or C-oligo before being stimulated or not with activin. Total cell lysates were then analyzed by Western blotting using antibodies to PRL or Stat3. As shown in Fig.  3B , the inhibitory effect of activin on PRL protein expression is abolished in the presence of AS-oligo, but not with the C-oligo.
To further support the essential role of menin in the regulation of PRL, we generated and tested three different siRNAs corresponding to the rat MEN1 gene. We used, as a control, an unrelated siRNA specific for GAPDH gene. As illustrated in Fig. 3C , transfection of MEN1 or GAPDH siRNA in GH4C1 cells efficiently reduced their respective mRNA and protein expression levels (55% inhibition). We chose to use M10 siRNA for subsequent experiments because this particular small interfering RNA (siRNA), which correspond to nucleotides 10-21 of the rat MEN1 coding sequence, was the most efficient in blocking menin mRNA expression. As shown in Fig. 3D , activin-medi- A and B, GH4C1 cells were cultured in the presence of menin antisense or control oligonucleotides and stimulated or not with activin for 24 h. Cell lysates were analyzed by Western blot using antibodies to menin, PRL, and Stat3 (as a loading control). C, Total RNA from GH4C1 cells transfected with menin (M10) or GAPDH siRNA were analyzed by RT-PCR. Total cell lysates from GH4C1 cells transfected with menin (M10) or GAPDH siRNA were analyzed by Western blot using antimenin and anti-Stat3 antibodies. D, GH4C1 cells transfected with M10 or GAPDH siRNA were cultured with or without activin for 24 h. Cell lysates were analyzed by Western blot using anti-PRL and antimenin antibodies. E, GH4C1 cells were transfected with the PRL-3kb reporter construct and the ␤-galactosidase expression plasmid. Cells were treated with menin antisense or control oligonucleotides and stimulated or not with activin for 18 h before being assessed for luciferase activity. *, P Ͻ 0.05 compared with no activin treatment. F, GH4C1 cells were cultured with activin for the indicated period of time. Protein extracts were analyzed by Western blot using a specific antibody to menin. The membrane was stripped and reprobed with an anti-Stat3 antibody. ated PRL expression inhibition was blocked in GH4C1 cells transfected with M10 siRNA but not affected in control cells or cells transfected with the GAPDH siRNA. Thus, reducing menin expression levels using siRNA or antisense approach, is sufficient to block activin-mediated PRL inhibition, demonstrating the critical role played by menin in activin signal transduction in pituitary cells.
We then analyzed the role of menin in activin-induced repression of the PRL gene promoter. For this, GH4C1 cells transfected with the 3-kb rat PRL gene promoter construct were treated with the menin antisense or control oligonucleotide, and cells were stimulated or not with activin. Interestingly, activin effects on the PRL gene promoter were completely blocked in the absence of menin but not affected by the control oligonucleotide (Fig. 3E) . Therefore, menin is critical and required to mediate activin effects on inhibition of PRL expression in anterior pituitary cells. We also examined the role of activin on menin expression. As shown in Fig. 3F , activin clearly induces an increase in menin expression in GH4C1 cells. As menin is required to mediate the activin effects (Fig. 3 , B-E), this suggests that it may act in a positive feedback loop to transduce activin signaling.
Activin-Dependent Down-Regulation of PRL Expression Is Pituitary Cell Specific
Production of PRL is not limited to the pituitary, and other sites such as the mammary gland (43) have been shown to produce PRL. Interestingly, the human breast cancer cell line T47D, which produces PRL (44) , is also responsive to activin (10) . However, as shown in Fig. 4A , no change in PRL expression (upper panel) was observed in response to activin in these cells. The activin responsiveness of the cells was demonstrated by the clear increase in phospho-Smad2 in response to activin (Fig. 4B) . Moreover, Chinese hamster ovary (CHO) cells, transiently transfected with the rPRL-3kb or rPRL-450bp gene promoter constructs, showed no decrease in luciferase activity in response to activin (Fig. 4C) . As a positive control, cells were transfected with the activin responsive promoter construct (3TPLux). Together, these data indicate that a pituitary cell-specific factor is involved in the activin-mediated down-regulation of PRL mRNA expression.
Pit-1 Gene Transcription and mRNA and Protein Levels Are Down-Regulated by Activin
Analysis of both the rat and human PRL promoterproximal region reveals three Pit-1 response elements, suggesting that activin-mediated PRL inhibition may be mediated via regulation of the pituitary-specific transcription factor Pit-1. This prompted us to analyze the regulation of Pit-1 gene expression by activin in GH4C1 cells. We first examined the activin effects on Pit-1 mRNA levels in GH4C1 cells. As shown in Fig.  5A , Northern blotting analysis of activin-treated GH4C1 cells indicated that Pit-1 mRNA levels were significantly reduced starting at 4 h to reach a maximum at 16 h after activin treatment. Pit-1 levels then returned to normal by 24 h. To then determine whether this decrease in Pit-1 mRNA was followed by a decrease in Pit-1 protein expression, GH4C1 cells stimulated with activin for different periods of time were analyzed by Western blot. As shown in Fig. 5B , both PRL and Pit-1 protein levels were strongly reduced upon activin treatment. To evaluate the role of menin in activin-mediated Pit-1 down-regulation, GH4C1 cells transfected with the menin siRNA (M10) or GAPDH siRNA were stimulated or not with activin, and the level of Pit-1 protein expression was evaluated using a specific anti-Pit-1 antibody. As shown in Fig. 5C , in the presence of menin siRNA, but not with GAPDH siRNA, activin lost its ability to repress Pit-1 protein expression, similar to that observed for PRL (Fig. 3C) , thus A, Breast cancer T47D cells were treated or not with activin for various times, as indicated. Cell lysates were analyzed by immunoblot using antibodies specific to PRL or Stat3 as control. B, T47D cells were stimulated with activin for 0, 15, 30, and 60 min. Protein extracts from these cells were then subjected to Western blot analysis with an anti-phosphoSmad2-specific antibody. The membrane was stripped and reprobed with an anti-Smad2/3-specific antibody. C, CHO cells were transfected with the PRL-3kb, the PRL-450bp, or the 3TP-lux reporter construct as a positive control with the ␤-galactosidase expression vector. Cells were then stimulated or not with activin and assessed for luciferase activity. *, P Ͻ 0.05 compared with no activin treatment.
indicating that menin is required for activin to block Pit-1 protein expression.
Furthermore, in GH4C1 cells transfected with a construct in which the Pit-1 gene promoter drives a luciferase reporter gene (45) , activin caused a 50% inhibition of luciferase activity, and this effect was blocked in cells expressing Smad7 (Fig. 5D ). These data indicate that activin modulates Pit-1 mRNA and protein expression in a Smad-and menin-dependent manner through inhibition of the Pit-1 gene promoter.
Pit-1 Response Elements in the PRL Gene Proximal Promoter Are Critical for ActivinMediated Repression
The proximal PRL gene promoter region contains three Pit-1 sites (Fig. 6A) . These sites are involved in both positive and negative regulation of PRL gene promoter activity (46) . To investigate the relative importance of these sites in mediating activin repression of the PRL promoter, four nucleotides of each Pit-1 DNA response element were mutated in the rPRL-3kb gene promoter construct to disrupt Pit-1 DNA binding activity (Fig. 6A) . Activin significantly inhibited the 3-kb parental promoter construct as well as the mutant promoter lacking the first Pit-1 site (Fig. 6B) . However, removal of either site 2 or site 3 completely reversed the activin-mediated inhibition of the PRL gene (Fig.  6B) . These results indicate that the Pit-1 sites 2 and 3, but not site 1, are important for activin-mediated repression of the PRL gene promoter activity.
Activin Inhibits Pituitary Cell Growth through Menin
Activin is known to induce growth inhibition of epithelial, endothelial, lymphoid, and hematopoietic cells. Therefore, to next investigate the effect of activin on pituitary cell growth, GH4C1 cells were stimulated or not with activin or TGF␤ as a control. As shown in Fig.  7A , both activin and TGF␤ significantly inhibited cell growth of GH4C1 cells by 30%, thus indicating that activin acts as a potent cell growth inhibitor of lactotrope cells. To explore the function of menin in activin signaling, GH4C1 cells stably overexpressing antisense menin cDNA (GH4-AS), in which menin expression levels are strongly reduced (34), or control GH4C1 cells expressing the vector alone (GH4-V) were treated or not with activin or TGF␤. Interestingly, both the activin and TGF␤ effect on cell growth inhibition were totally blocked in the absence of menin (Fig. 7A) . To confirm these results, we used other means of blocking menin expression by utilizing modified phosphorothioate antisense oligonucleotides to menin. As shown in Fig. 7B , the effects of activin and TGF␤ on GH4C1 cell growth arrest were specifically antagonized and completely reversed in the presence of menin AS-oligo whereas they were not affected by the control oligonucleotide. These data demonstrate that activin acts as a potent pituitary tumor cell growth inhibitor and that this effect requires the tumor suppressor, menin.
DISCUSSION
Members of the activin/TGF␤ family of growth factors are important in regulating cell growth and production of a variety of hormones from different pituitary cell types. Our study defines a critical role for activin in regulating the growth and function of pituitary lactotrope cells. We demonstrate for the first time the requirement of the Smad pathway and the tumor suppressor menin in transducing activin signals to inhibition of PRL expression and cell growth arrest.
Our results also indicate that activin-mediated effects on PRL production are pituitary specific. PRL transcription is controlled through a series of distal and proximal enhancer elements that contain several DNA binding sites for the transcription factor Pit-1 that are required to regulate cell-specific expression (47) . Our results clearly indicate that activin exerts a direct negative effect on Pit-1 gene expression. Thus, inhibition of Pit-1 expression by activin contributes to the decreased PRL level. Our data strongly support previous observations showing that extinction of PRL and GH gene expression in somatic cell hybrids is correlated with the repression of Pit-1 (48, 49) . Interestingly, previous work showed that activin could contribute to reduced intracellular Pit-1 levels by decreasing its stability (31) . Together with our results, this indicates that activin is able to down-regulate intracellular Pit-1 and PRL levels through different parallel mechanisms, highlighting the critical role played by activin in regulating pituitary hormone levels.
A previous study in GH3 pituitary cells found no apparent change in Pit-1 mRNA levels after activin stimulation of the cells for 24 h (30). Based on our study, activin-mediated repression of Pit-1 mRNA is a transient event that occurs within hours of stimulation and returns to normal by 24 h, thus explaining why Tamura et al. (30) failed to observe any change in Pit-1 mRNA in activin-treated cells.
Moreover, the inhibitory effect of activin on GH production is mediated through rapid phosphorylation of Pit-1, resulting in loss of DNA binding activity and protein instability (31) . Together with our results, this suggests that activin acts at multiple levels to regulate Pit-1 and hormonal levels in pituitary cells.
We also show that the proximal, but not the distal, region of the PRL gene promoter mediates the activininhibitory effects. This proximal region of the PRL gene promoter contains three Pit-1 response elements, and we show here that sites 2 and 3 are each required for activin to repress PRL gene expression. Therefore, this suggests that activin-mediated inhibition of PRL expression is not only mediated through a direct downregulation of Pit-1 gene expression but also through prevention of DNA binding of the preexisting pool of Pit-1 on sites 2 and 3 of the PRL gene promoter. Such interference with DNA binding and activating functions of Pit-1 has been described as a mechanism by which glucocorticoids inhibit PRL expression (46) . Interestingly, negative regulation of PRL expression by glucocorticoids involves the same proximal Pit-1 sites 2 and 3, suggesting that this may represent a general mechanism of negative regulation of PRL gene transcription.
It is also possible that activin induces recruitment of a corepressor to the Pit-1 complex bound to DNA. Activin and TGF␤ are known to recruit histone deacetylases to some of their target genes, inhibiting their transcription (50) . Pit-1 has also been shown to mediate transcriptional activation and repression by recruitment of coactivators or corepressors (51, 52) . It will therefore be interesting in future studies to determine whether the Smads physically interact with Pit-1 and/or histone deacetylase activity can be found in these complexes.
Whereas Smads, menin and Pit-1, are critical to activin inhibition of PRL gene expression, a previous study suggested that the inhibitory effect of TGF␤ on the rat PRL gene promoter is Pit-1-independent (53). Therefore, our results also highlight significant differences in the intracellular signaling pathways of these two growth factors leading to PRL gene regulation in pituitary cells.
Inactivating alterations in the activin/TGF␤ signaling pathways have been described to form the basis of many human cancers (54) . For instance, Smad2 and Smad4 are frequently mutated in colorectal cancers and pancreatic carcinomas, respectively (54) . Truncated activin receptor forms are often found in human pituitary adenomas and function as dominant negative receptors, contributing to pituitary tumorigenesis by blocking the growth-inhibitory effect of activin (17) . MEN1 is an autosomal dominant disorder characterized by parathyroid hyperplasia, pancreatic endocrine tumors, and pituitary adenomas (32) . Pituitary tumors occur in 30% of MENI patients, with prolactinomas being the most common type (56) . Twenty-six percent of mice heterozygous for deletion of the MEN1 gene develop large pituitary tumors by 16 months of age (57) . Here, we demonstrate that inactivation of menin through three different antisense technologies (cDNA antisense, oligonucleotide antisense, and siRNA) blocks activin signaling. This results in an increase in PRL gene expression, Pit-1 gene expression, and the loss of pituitary cell growth inhibition by activin. This is consistent with our previous work showing that inactivation of menin interrupts Smad3 binding to DNA, thereby blocking TGF␤ signaling (34) . Thus, menin appears as a novel activin downstream signaling effector molecule, and its inactivation leads to the loss of activin/TGF␤ responses, emphasizing the critical role played by these growth factors in maintaining cellular homeostasis.
Pituitary adenoma is the most frequent adult intracranial neoplasm, accounting for 10% of brain tumors, and, in contrast to other neoplasms, occurs in younger patients. Prolactinomas are the most common hormone-secreting pituitary tumor, accounting for twothirds of the patients in a pituitary tumor registry across the fourth decade (58) . Prolactinomas often develop sporadically as a monoclonal proliferation, but the molecular mechanisms underlying the formation of these tumors remain largely unknown. Gene expression of Pit-1 has been explored in pituitary adenomas but revealed no mutation of the Pit-1 gene in these tumors, despite an up to 5-fold higher level of Pit-1 as compared with normal (59). To date, standard primary treatment using dopamine agonists showed suppressive, but not tumoricidal, effects with side effects and varying remission rates (60, 61) . As for patients with therapeutic intolerance or insensitivity to dopamine agonists, surgery remains the last resort. Our study sheds light on the mechanisms by which activin regulates PRL, Pit-1 levels, and cell growth arrest in lactotrope cells, through the Smad pathway and the tumor suppressor menin, and opens new avenues for future therapies to combat human pituitary adenomas. 
MATERIALS AND METHODS
Cell
Transfection and Reporter Assays
GH4C1 cells were stably transfected with antisense menin cDNA as described (34) . For luciferase assays, 0.3 g of the different promoter constructs (rat PRL-lux 3kb, rat PRL-lux 450, rat PRL-lux mutants, human PRL-lux 5kb, human PRLlux 250, and Pit-1-lux) were cotransfected in 10 6 cells with Lipofectamine (Invitrogen, Carlsbad, CA) with 0.3 g of the pCH110 expression vector encoding ␤-galactosidase, in the presence or absence of various Smad expression plasmids, as described in the legend of Fig. 2 . Cells were trypsinized 1 d after transfection, divided in three, allowed to recover, and then serum-starved with or without activin (0.5 nM) or TGF␤ (0.2 nM) for 18 h. Cells were then washed with PBS and lysed in 100 l lysis buffer (1% Triton X-100; 15 mM MgSO 4 ; 4 mM EGTA; 1 mM dithiothreitol; 25 mM glycylglycine, pH 7.8) on ice. The luciferase activity of each sample was measured using 45 l cell lysate (luminometer from EG&G Berthold, Badwildbad, Germany) and normalized to the relative ␤-galactosidase activity. CHO cells were transfected using the calcium phosphate method. Briefly, 1 g of the different reporter constructs were transfected with 1 g ␤-galactosidase expression vector. Cells were serum-starved 1 d after transfection, in the presence or absence of 0.5 nM activin, for 18 h. Luciferase assays were performed as for GH4C1 cells.
Western Blot Analysis
For long time courses (0-24 h), GH4C1 and T47D cells were plated at 10 6 cells/ml in DMEM containing 2% FBS and stimulated in the presence or absence of 0.5 nM activin. For short time courses (0-60 min), cells were serum starved overnight, and stimulated or not with 0.5 nM activin. Cells were lysed on ice in lysis buffer [50 mM HEPES at pH 7.5, 150 mM sodium chloride, 100 mM sodium fluoride, 10 mM sodium pyrophosphate, 5 mM EDTA, 10% glycerol, 0.5% Nonidet P40, and 0.5% sodium deoxycholate] supplemented with 1 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 10 g/ml leupeptin, and 2 g/ml pepstatin. Total cell extracts were then separated on polyacrylamide gels, transferred to nitrocellulose, and incubated with the indicated specific antibody overnight at 4 C [menin (62) , stat3 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), PRL, phospho-Smad2 (Upstate Biotechnology, Inc., Lake Placid, NY), Smad2/3 (Santa Cruz), tubulin (Sigma Chemical Co., St. Louis, MO), Pit-1 (Santa Cruz)]. After incubation, membranes were washed twice for 10 min in washing buffer (50 mM Tris-Cl at pH 7.6, 200 mM NaCl, 0.05% Tween 20) and incubated with a secondary antibody coupled to horseradish peroxidase (Sigma) at 1:10,000 dilution) for 1 h at room temperature. Then, membranes were washed four times for 15 min in washing buffer. Immunoreactivity was normalized by chemiluminescence (Lumi-Light Plus Western blotting substrate, Roche Molecular Biochemicals, Indianapolis, IN) according to the manufacturer's instructions and revealed using an Alpha Innotech Fluorochem Imaging system (Packard Canberra, Montreal, Quebec, Canada). Densitometric analysis was performed using Fluorochem 8000 software (Alpha Innotech, San Leandro, CA) that allows normalization and quantitative analysis of chemiluminescence under nonsaturating condition.
Northern Blot Analysis
GH4C1 (10 6 cells/ml) were plated in DMEM containing 2% FBS and stimulated with 0.5 nM activin for different periods of time. Total RNA was extracted using Trizol (Invitrogen). Each sample (20 g) was then separated on agarose gels (1% agarose in 0.04 M 3-(N-morpholino)propanesulfonic acid; 0.01M sodium acetate; 10 mM EDTA, pH 8.0; and 2.5M formaldehyde) and transferred to nylon membranes. Membranes were rinsed twice in 10ϫ standard saline citrate, cross-linked under UV light, and prehybridized in a prehybridization solution (0.5M NaPO 4 , pH 7.2; 1 mM EDTA, pH 8.0; 7% sodium dodecyl sulfate (SDS); 1% BSA; and 200 g/ml salmon sperm DNA) for 2 h at 60 C. Probes for PRL, Pit-1, and GAPDH were labeled using the Random Priming Kit (Roche), and then add to the prehybridization solution for an overnight incubation. Membranes were washed twice for 15 min with wash A (40 mM NaPO 4 , pH 7.2; 5% SDS; 1 mM EDTA; and 0.5% BSA), and four times with wash B (40 mM NaPO 4 , pH 7.2; 1% SDS; 1 mM EDTA). Results were revealed using a phosphor imager Cyclone Storage Phosphor Screen (Packard Instruments, Meriden, CT).
Antisense Oligonucleotide (AS-Oligo) Treatment
Phosphorothioate-derivatized antisense menin and control oligonucleotides (C-oligos) (20 bp) were synthesized. The AS-oligo was 5Ј-GGGCGGCCTTCAGCCCCATG-3Ј, and the C-oligo was 5Ј-TCAGACTGGCTCTCTCCATG-3Ј. Cells were plated in the presence or absence of 100 M menin AS-oligo or control C-oligo for 12 h and then stimulated with 0.5 nM activin or 0.2 nM TGF␤. Luciferase activity was measured after 18 h and cell growth was measured after 72 h of ligand stimulation.
Mutagenesis of the rPRL Promoter
The three Pit-1 proximal binding sites in the wild-type PRL3kb construct were mutated singly to disrupt DNA binding of Pit-1 using the QuikChange mutagenesis kit (Stratagene, La Jolla, CA). Oligonucleotides used for mutagenesis were: mut-1P, 5Ј-GCCTGATTATATATATGGGAATGAAGGTGTCG-AAGG-3Ј and 5Ј-CCTTCGACACCTTCATTCCCATATATATA-ATCAGGC-3Ј; mut-2P, 5Ј-GGCCACTATGTCTTCCTGAAT-ATTCCGAAGAAATAAAATACCATTTGA-3Ј and 5Ј-TCAAA-TGGTATTTTATTTCTTCGGAATATTCAGGAAGACATAGTG-GCC-3Ј; mut-3P, 5Ј-TCATTTCCTTTTGCTGTAATTGCGAAA-AATCCTTCCTTTCTGGCC-3Ј and 5Ј-GGCCAGAAAGGAAG-GATTTTTCGAAATTACAGCAAAAGGAAATGA-3Ј. The mutated nucleotides are indicated in bold. All mutant constructs were confirmed by sequencing.
siRNA Design, Generation, and Transfection
Three different siRNAs corresponding to distinct parts of the rat MEN1 gene (GenBank accession no. 9506894) were designed using the siRNA Selection Program (Whitehead Institute for Biomedical Research, Cambridge, MA). All siRNA sequences were Blast searched in the National Center for Biotechnology Information search for short-nearly exactmatches mode against all rat sequences of the GenBank database and were not found to have significant homology to genes other than the rat MEN1 gene. siRNAs were synthetized using the Silencer siRNA Construction Kit (Ambion, Inc., Austin, TX) according to the manufacturer's instructions. SiRNAs sequences were as follows: M10 5Ј-AAGGCCGC-CCAGAAGACGCTG-3Ј; M379 5Ј-AACAGCCTCAGCCGC-TCCTAC-3Ј; M1073 5Ј-AAGAGATCTACAAGGAATTCT-3Ј. GAPDH siRNA was provided with the kit. GH4C1 cells (5 ϫ 10 4 ) were transfected using the siPORT Lipid transfection agent (Ambion) according to the manufacturer's instructions. Expression levels of menin, PRL, and Pit-1 were analyzed by Western blot and RT-PCR.
Statistical Analysis
Results are expressed as mean Ϯ SD. Differences were assessed by one-way ANOVA or the unpaired t test, where appropriate. P Ͻ 0.05 was considered significant.
